Phase 2 N=9 Safety and Tolerability of Dabigatran Etexilate in Adolescents
Venous Thromboembolism
Primary: Number of Patients With Bleeding Events (Major and Minor) — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=285 Epiduo Pediatric Acne Study
Acne
Primary: Success Rate — 47.2; 15.4 percentage of participant — p=<0.001
Phase 3 N=102 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
Colorectal Cancer · Neurotoxicity
Primary: Percentage of Patients With Oxaliplatin-induced Grade 2+ Chronic Neuropathic Adverse Event — 22; 41 Percentage of participants — p=0.038
Phase 2 N=30 Study of Capecitabine to Treat Recurrent High Grade Gliomas
Malignant Glioma
Primary: Percentage of Participants With Progression-free Survival. — 21.7 percentage of participants with PFS6
Phase 4 N=115 An Efficacy and Safety Study of Miconazole and Hydrocortisone Cream in the Treatment of Vulvar Candidiasis
Vulva; Candidiasis
Primary: Mean Time to Itch Relief — 13.36 minutes
N/A N=306 Prevention of Intraoperative Nausea and Vomiting During Cesarean Section
Cesarean Delivery
Primary: Intraoperative Nausea and Vomiting — 23; 31; 49 participants
Phase 4 N=45 An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Severe Chronic Low Back Pain
Low Back Pain
Primary: Pain Intensity at Day 15 — 4.85 cm
Phase 2 N=565 Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Irritable Bowel Syndrome With Diarrhea
Primary: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With…
Phase 3 N=506 Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) — -0.42; -0.99; -0.22; -0.91 percentage glycosylated hemoglobin — p=<0.001
N/A N=50 Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)
Sarcoma · Nausea · Vomiting
Primary: Palonosetron Response Rate in the 10 Day Study Cycle — 31.25; 50 percentage of participants
Phase 3 N=440 Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers
Influenza
Primary: Geometric Mean Titer — 3.36; 2.61; 2.46; 2.41 GMT fold increase from baseline
Phase 2 N=69 Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
Pancreatic Cancer
Primary: Overall Survival Rate — 66.0; 25.02; 11.3 percentage of participants
N/A N=60 Hemodynamic Responses During Induction: Comparison of Marsh and Schnider Pharmacokinetic Models
Healthy
Primary: SVI (Stroke Volume Index) Value Change From Baseline Level at the End of the First 25 Minutes. — -31.1; -31.7 ml/beat/m^2
Phase 4 N=35 Circadian Ocular Perfusion Pressure and Ocular Blood Flow
Glaucoma
Primary: Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6 — 2.6; 0.8 mmHg (millimeters of mercury)
Phase 4 N=100 Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic
Alcohol Dependence
Primary: % Dropout — 21.5; 16.3 percentage of participants